Treatment of Parkinson's Disease and Restless Legs Syndrome With Cabergoline, a Long‐acting Dopamine Agonist

Abstract

SUMMARYDopamine agonists have diverse chemical and physical properties that can directly stimulate the dopamine receptors, unlike levodopa which undergoes presynaptic breakdown to dopamine before dopaminergic effects in Parkinson's disease (PD). Cabergoline, a dopamine agonist effective given once daily, is being used as treatment for PD. In theory, therapy with cabergoline provides striatal intrasynaptic dopamine replacement of PD in a physiological manner because of its long half‐life and the resultant sustained rather than pulsatile dopaminergic stimulation. Several placebo‐controlled trials using cabergoline as adjunctive therapy in PD have shown that cabergoline significantly reduces ‘off’ time, improves motor function and reduces levodopa requirement. Cabergoline has also been used as monotherapy in PD and has been shown to be as effective as other dopamine agonists in improving motor function and to be superior to levodopa in reducing dyskinesias over a five‐year period. Work from our group and others have also demonstrated the efficacy of cabergoline in PD patients with nocturnal disabilities and those with restless legs syndrome (RLS). More recently we have reported that cabergoline is a well‐tolerated dopamine agonist in both young and elderly patients and has an acceptable side‐effect profile.